Research Analysts’ Recent Ratings Changes for Hims & Hers Health (HIMS)

Several brokerages have updated their recommendations and price targets on shares of Hims & Hers Health (NYSE: HIMS) in the last few weeks:

• 7/13/2026 – Hims & Hers Health was upgraded by Zacks Research from “strong sell” to “hold”.
• 7/9/2026 – Hims & Hers Health had its price target raised by Bank of America Corporation from $36.00 to $37.00. They now have a “neutral” rating on the stock.
• 7/1/2026 – Hims & Hers Health had its price target raised by Canaccord Genuity Group Inc. from $32.00 to $40.00. They now have a “buy” rating on the stock.
• 7/1/2026 – Hims & Hers Health had its price target raised by Bank of America Corporation from $25.00 to $36.00. They now have a “neutral” rating on the stock.
• 6/17/2026 – Hims & Hers Health had its price target raised by Barclays PLC from $29.00 to $39.00. They now have an “overweight” rating on the stock.
• 6/8/2026 – Hims & Hers Health was downgraded by Zacks Research from “hold” to “strong sell”.
• 5/26/2026 – Hims & Hers Health had its price target lowered by Bank of America Corporation from $28.00 to $25.00. They now have a “neutral” rating on the stock.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Irene Becklund sold 4,490 shares of the stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total value of $141,435.00. Following the sale, the insider directly owned 6,790 shares of the company’s stock, valued at approximately $213,885. This represents a 39.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Michael Chi sold 14,027 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the sale, the chief operating officer owned 432,124 shares in the company, valued at $13,611,906. The trade was a 3.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 83,126 shares of company stock worth $2,711,339 over the last quarter. 11.76% of the stock is currently owned by insiders.

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.